Literature DB >> 15245485

Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background.

Elise Morice1, Cécile Denis, Bruno Giros, Marika Nosten-Bertrand.   

Abstract

The dopamine transporter (DAT) plays a critical role in calibrating the duration and intensity of dopamine (DA) neurotransmission. Mice in which the DAT gene has been genetically deleted exhibit constitutively high levels of extrasynaptic DA and spontaneous hyperactivity. Numerous studies have characterized the adaptive molecular, physiological, and behavioural consequences of abnormal DA neurotransmission in these mice. In order to determine the genetic background contribution to these phenotypes, the DAT mutation was transferred on C57BL/6JOrl (B6) or DBA/2JOrl (D2) inbred backgrounds for more than ten generations of back-crossing to derive three B6-, D2-, and B6xD2(F(1))-DAT strains. We observed that the genetic background dramatically affects phenotypes previously reported on DAT knockout (KO) mice. Depending on the genetic background, it was possible to restore survival, growth rate and ability to lactate. Interactions with the genetic background were found to modulate both quantitative and qualitative patterns of novelty-driven spontaneous hyperactivity. The paradoxical calming effect of cocaine was observed for all DAT-KO mice. However, the genetic background influenced individual threshold responses to both locomotor and rewarding effects of cocaine. These findings reveal the extent of phenotypic variation associated with the DAT mutation. They also provide concrete arguments against the assumption that the normal function of a gene can be inferred directly from its mutant phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245485     DOI: 10.1111/j.1460-9568.2004.03465.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  31 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 3.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study.

Authors:  Silvia Mandillo; Valter Tucci; Sabine M Hölter; Hamid Meziane; Mumna Al Banchaabouchi; Magdalena Kallnik; Heena V Lad; Patrick M Nolan; Abdel-Mouttalib Ouagazzal; Emma L Coghill; Karin Gale; Elisabetta Golini; Sylvie Jacquot; Wojtek Krezel; Andy Parker; Fabrice Riet; Ilka Schneider; Daniela Marazziti; Johan Auwerx; Steve D M Brown; Pierre Chambon; Nadia Rosenthal; Glauco Tocchini-Valentini; Wolfgang Wurst
Journal:  Physiol Genomics       Date:  2008-05-27       Impact factor: 3.107

Review 5.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

6.  Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice.

Authors:  Morgane Thomsen; F Scott Hall; George R Uhl; S Barak Caine
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 7.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

8.  Evidence of long-term expression of behavioral sensitization to both cocaine and ethanol in dopamine transporter knockout mice.

Authors:  Elise Morice; Cécile Denis; Bruno Giros; Marika Nosten-Bertrand
Journal:  Psychopharmacology (Berl)       Date:  2009-11-24       Impact factor: 4.530

Review 9.  Implications of genome wide association studies for addiction: are our a priori assumptions all wrong?

Authors:  F Scott Hall; Jana Drgonova; Siddharth Jain; George R Uhl
Journal:  Pharmacol Ther       Date:  2013-07-18       Impact factor: 12.310

10.  The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.

Authors:  Denis Boulay; Olivier Bergis; Patrick Avenet; Guy Griebel
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.